1-8 of 8
Natalie M Czuczman
Close
Sort by
Journal Articles

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Natalie M. Czuczman, Matthew J. Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E. Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood
Blood (2016) 127 (9): 1128–1137.
https://doi.org/10.1182/blood-2015-04-640920
Published: 2016
Includes: Supplemental data
Journal Articles

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan S Lim, MD PhD, Aradhana Tiwari, Mitchell S. Cairo, MD, Rodney R. Miles, MD PhD, Matthew J. Barth, MD
Journal: Blood
Blood (2014) 124 (21): 1769.
https://doi.org/10.1182/blood.V124.21.1769.1769
Published: 2014
Journal Articles

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Andrew Skomra, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan Lim, MD, PhD, Aradhana Awasthi, Ph.D, Mitchell S. Cairo, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD
Journal: Blood
Blood (2013) 122 (21): 5144.
https://doi.org/10.1182/blood.V122.21.5144.5144
Published: 2013
Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2013) 122 (21): 647.
https://doi.org/10.1182/blood.V122.21.647.647
Published: 2013
Journal Articles

Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.

Natalie M Czuczman, Matthew J. Barth, MD, Richa Dwar, Cory Mavis, BSc, MSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2012) 120 (21): 2761.
https://doi.org/10.1182/blood.V120.21.2761.2761
Published: 2012
Journal Articles

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, Karen E Thudium, George Deeb, MD, John Gibbs, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2011) 118 (21): 4967.
https://doi.org/10.1182/blood.V118.21.4967.4967
Published: 2011
Journal Articles

The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death

Juan Gu, PhD, Natalie M Czuczman, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2011) 118 (21): 4970.
https://doi.org/10.1182/blood.V118.21.4970.4970
Published: 2011
Journal Articles

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Matthew J. Barth, MD, Gopichand Pendurty, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2011) 118 (21): 4972.
https://doi.org/10.1182/blood.V118.21.4972.4972
Published: 2011